Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps
2024-516814-39-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Itepekimab with Matched placebo (2 arms). Primary endpoints: Change from baseline in endoscopic Nasal Polyp Score and Change from baseline in Nasal Congestion Score. Planned start Mar 2025; status: authorised.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2024-516814-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516814-39-00.